Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
NCT07573163 on ClinicalTrials.gov · last registry update 2026-07-30
A small phase 2 — 34 participants, against a typical 110. Due to report 31 July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Change in systolic blood pressure. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- Alaa Sada
- Sponsor type
- Other
- Enrollment
- 34
- Started
- 2026-07-27
- Primary completion
- 2028-07-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in systolic blood pressure
Conditions studied
Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.